{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:55:07Z","timestamp":1777114507083,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,26]]},"DOI":"10.7759\/cureus.102345","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:17:00Z","timestamp":1769480220000},"source":"Crossref","is-referenced-by-count":1,"title":["Cabergoline-Resistant Recurrent Macroprolactinoma During Pregnancy: A Case Report and Review of the Literature"],"prefix":"10.7759","author":[{"given":"Sharvani","family":"Alajpur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram Jeet Singh","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aislinn","family":"McCleery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathleen   J","family":"Mullarkey-Desapio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter D","year":"2019","unstructured":"Maiter D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2019, 109:42-50. 10.1159\/000495775","journal-title":"Neuroendocrinology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam MP","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006, 27:485-534. 10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0462","article-title":"ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger A","year":"2021","unstructured":"Luger A, Broersen LH, Biermasz NR, et al.. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021, 185:G1-G33. 10.1530\/EJE-21-0462","journal-title":"Eur J Endocrinol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed S","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96:273-88. 10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients","volume":"160","author":"Delgrange E","year":"2009","unstructured":"Delgrange E, Daems T, Verhelst J, Abs R, Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol. 2009, 160:747-52. 10.1530\/EJE-09-0012","journal-title":"Eur J Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0236","article-title":"Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients","volume":"167","author":"Vroonen L","year":"2012","unstructured":"Vroonen L, Jaffrain-Rea ML, Petrossians P, et al.. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol. 2012, 167:651-62. 10.1530\/EJE-12-0236","journal-title":"Eur J Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0656","article-title":"Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels","volume":"166","author":"Shimazu S","year":"2012","unstructured":"Shimazu S, Shimatsu A, Yamada S, Inoshita N, Nagamura Y, Usui T, Tsukada T. Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. Eur J Endocrinol. 2012, 166:383-90. 10.1530\/EJE-11-0656","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-020-01085-5","article-title":"AIP variant causing familial prolactinoma","volume":"24","author":"Carty DM","year":"2021","unstructured":"Carty DM, Harte R, Drummond RS, et al.. AIP variant causing familial prolactinoma. Pituitary. 2021, 24:48-52. 10.1007\/s11102-020-01085-5","journal-title":"Pituitary"},{"key":"ref9","article-title":"Ki-67 and clinical correlations in patients with resistant prolactinomas","volume":"50","author":"Lu C","year":"2020","unstructured":"Lu C, Liu Y, Lu Z, Huan C. Ki-67 and clinical correlations in patients with resistant prolactinomas. Ann Clin Lab Sci. 2020, 50:199-204.","journal-title":"Ann Clin Lab Sci"},{"key":"ref10","article-title":"Managing the challenges of pregnancy in a case of recurrent macroprolactinoma: a balancing act","volume":"39","author":"Chowdhury P","year":"2026","unstructured":"Chowdhury P, Tofail T. Managing the challenges of pregnancy in a case of recurrent macroprolactinoma: a balancing act. J Clin Transl Endocrinol Case Rep. 2026, 39:100211.","journal-title":"J Clin Transl Endocrinol Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04373.x","article-title":"Temozolomide in the management of dopamine agonist-resistant prolactinomas","volume":"76","author":"Whitelaw BC","year":"2012","unstructured":"Whitelaw BC, Dworakowska D, Thomas NW, et al.. Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf). 2012, 76:877-86. 10.1111\/j.1365-2265.2012.04373.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans EC","year":"2019","unstructured":"Coopmans EC, van Meyel SW, Pieterman KJ, et al.. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. Eur J Endocrinol. 2019, 181:K21-7. 10.1530\/EJE-19-0279","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-013-1351-8","article-title":"Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models","volume":"116","author":"Cao L","year":"2014","unstructured":"Cao L, Gao H, Gui S, Bai G, Lu R, Wang F, Zhang Y. Effects of the estrogen receptor antagonist fulvestrant on F344 rat prolactinoma models. J Neurooncol. 2014, 116:523-31. 10.1007\/s11060-013-1351-8","journal-title":"J Neurooncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000344","article-title":"Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside","volume":"24","author":"Ben-Shlomo A","year":"2017","unstructured":"Ben-Shlomo A, Cooper O. Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside. Curr Opin Endocrinol Diabetes Obes. 2017, 24:301-5. 10.1097\/MED.0000000000000344","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-15-0451","article-title":"The pituitary TGF\u03b21 system as a novel target for the treatment of resistant prolactinomas","volume":"228","author":"Recouvreux MV","year":"2016","unstructured":"Recouvreux MV, Camilletti MA, Rifkin DB, D\u00edaz-Torga G. The pituitary TGF\u03b21 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol. 2016, 228:R73-83. 10.1530\/JOE-15-0451","journal-title":"J Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000517356","article-title":"MicroRNAs in dopamine agonist-resistant prolactinoma","volume":"112","author":"Wan X","year":"2022","unstructured":"Wan X, Yan Z, Tan Z, et al.. MicroRNAs in dopamine agonist-resistant prolactinoma. Neuroendocrinology. 2022, 112:417-26. 10.1159\/000517356","journal-title":"Neuroendocrinology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-023-02010-w","article-title":"CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma","volume":"46","author":"Wu N","year":"2023","unstructured":"Wu N, Zhu D, Li J, et al.. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma. J Endocrinol Invest. 2023, 46:1573-87. 10.1007\/s40618-023-02010-w","journal-title":"J Endocrinol Invest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415865-cabergoline-resistant-recurrent-macroprolactinoma-during-pregnancy-a-case-report-and-review-of-the-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T02:17:02Z","timestamp":1769480222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415865-cabergoline-resistant-recurrent-macroprolactinoma-during-pregnancy-a-case-report-and-review-of-the-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.102345","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,26]]}}}